{"prompt": "['12', '1.7.2 Supporting Variables', 'The supporting variables will be recorded by the Standard (ST) investigation for DR and', 'AMD.', 'No of', 'Test', 'Variable', 'Unit', 'instances', 'Unit description', 'GAT', '1', 'Pressure', 'mmHg', '2 digits, 1 decimal', 'iCare', '1', 'Pressure', 'mmHg', '2 digits, 1 decimal', 'Acuity chart', '1', 'Visual acuity', 'logMAR', '1 digit, 1 decimal', 'Contrast chart', '1', 'Contrast acuity', 'Pelli-Robson score', '1 digit, 2 decimals', '1', 'Nasal step', '1', 'Temporal wedge', '1', 'Partial arcuate (sup)', '1', 'Partial arcuate (inf)', 'Boolean', '1', 'Arcuate (sup)', 'Present', '1', '(true / false)', 'Arcuate (inf)', '1', 'Altitudinal (inf)', '1', 'Altitudinal (sup)', '1', 'Paracentral', 'MD', 'dB', '2 digits, 2 decimals', 'Visual field', '54', 'X coordinate', 'Degrees', '3 digits, 1 decimal', 'Y coordinate', 'Degrees', '3 digits, 1 decimal', '1', 'Threshold sensitivity', 'dB', '2 digits, 2 decimals', '1', 'Percentile degree', 'Score 1-5', '1 digit', '1', 'Defuse defect', 'dB', '2 digits, 1 decimal', '1', 'Local defect', 'dB', '2 digits, 1 decimal', '1', 'sLV', 'dB', '2 digits, 1 decimal', '1', 'False positive', 'Percent (Reliability)', '2 digits', '1', 'False negative', 'Percent (Reliability)', '2 digits', '1', 'Reliability factor', 'Percent (Reliability)', '2digits, 1 decimal', '1', 'Mean Sensitivity', 'dB', '2 digits, 1 decimal', 'OCT RNFL', '1', 'Average thickness', 'um', '3 decimals', 'OCT GCL', '1', 'Volume', 'mm^3', '3 decimals', 'Pupil', '1', 'Diameter change (max-min)', 'mm', '1 digit, 2 decimals', 'The central variables related to DR and AMD will be \"RAPD NDF\", \"Seen/unseen \",\"Time', 'until the given point is recorded as seen\", \"the light in decibel when the point is seen\", X- and', 'Y-coordinates and \"Pupil diameter in mm\" and \"OCT RNFL', '1.8: Study procedure', 'Participants, who fulfil the inclusion criteria; do not meet any of the exclusion criteria and', 'willing to give informed consent to participate will receive an appointment for starting the', 'study. The Bulbicam examination will be performed twice a day with a rest period of one', 'hour between each registration. This procedure will be repeated the following two days. All', 'demographic data, social factors and history of disease will be recorded at screening.', 'Additionally, the quality of life (QoL) questionnaires EQ-5D-5L developed by EuroQol will', 'be recorded initially as individual baseline values.', 'The Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be used for', 'measuring and classifying the tolerability and toxicity at the end of each day of investigation.', 'BulbiCam; Validity study:', 'V1_OTH/DR; AMD-I/2022:', 'Final Version 1.5 22nd March 2022']['13', '1.9: Sample size', 'Sixteen DR patients and 16 AMD patients from each of the two categories will be recruited', 'from the two participating hospitals. All together a total of 16x2=32 patients will be included.', 'For each included patient, one gender- and age-matched HC will be recruited. In total 32 HC.', '1.10: Time schedule', 'The study duration for each participant will be 3 days including six measurements using', 'Bulbicam and one using the Standard method. The recruitment period is nine months. The', 'total duration of the study will be as follows:', 'Inclusion of the first patient with control', '01-05-2022', 'End of trial; last patient with control', '15-01-2023', 'Closing database', '15-02-2023', 'Finalized Clinical Study Report', '01-03-2023', '1.11: Flow chart', 'Screening', 'Day 1;', 'Day 2;', 'Day 3;', 'Repeatability', 'Stability-1', 'Stability-2', 'Inclusion and Exclusion criteria', 'X', 'Oral & written informed consent', 'X', 'Patient factors', 'X', 'History of disease', 'X', 'Eye-examination.', 'X', 'Concom. Medicine', 'X', 'X', 'X', 'X', 'Quality of Life', 'X', 'Bulbicam tests', 'Visual Field', 'X', 'X', 'X', 'Ptosis', 'X', 'X', 'X', 'Dynamic Acuity', 'X', 'X', 'X', 'Dynamic Contrast', 'X', 'X', 'X', 'Dark Adaption', 'x', 'X', 'X', 'Pupil', 'X', 'X', 'X', 'Standard Method', 'GAT', 'X', 'ICare', 'X', 'Visual Field', 'X', 'Pupil', 'X', 'OCT RNFL', 'X', 'OCT GCL', 'X', 'Adverse Events [CTCAE]', 'X', 'x', 'X', 'x', 'End of study', 'x', 'BulbiCam; Validity study:', 'V1_OTH/DR; AMD-I/2022:', 'Final Version 1.5 22nd March 2022']\n\n###\n\n", "completion": "END"}